Is dupixent safe for long term use in kids?

Is Dupixent safe for long-term use in children

Dupixent is approved for children as young as six months old for moderate-to-severe atopic dermatitis and for children six years and older for moderate-to-severe asthma and eosinophilic esophagitis. Long-term safety data come from extension studies that followed pediatric patients for up to three years. These studies show that the rate of adverse events remains stable and does not increase over time. Common side effects in children include injection-site reactions, conjunctivitis, and cold symptoms; serious infections or new safety signals have not been observed beyond those seen in adults.

When should parents consider stopping Dupixent

Clinicians usually continue treatment as long as the child continues to benefit and no unacceptable side effects occur. There is no fixed maximum duration. If a child reaches sustained disease control, doctors may discuss spacing injections or pausing therapy to see whether symptoms return. Regular follow-up visits, growth monitoring, and periodic lab checks are recommended for any child on long-term therapy.

How do long-term results in children compare with adults

Extension trials in both age groups show similar safety profiles. Children experience fewer injection-site reactions than adults and comparable rates of eye inflammation. Growth parameters, bone age, and pubertal development have not been adversely affected in the pediatric cohorts studied so far.

What monitoring is needed during extended treatment

Pediatric patients should have height and weight measured at every visit. Eye examinations are advised at baseline and periodically if symptoms of conjunctivitis appear. Because Dupixent blocks IL-4 and IL-13 signaling, clinicians watch for parasitic infections in children who live in or travel to endemic areas. Vaccinations should be kept up to date, and live vaccines are avoided while on therapy.

Can children stay on Dupixent into adulthood

Many children who start Dupixent for severe eczema or asthma continue treatment without interruption as they transition to adult care. Registries tracking these patients will provide longer-term data on whether extended use alters infection risk or immune development.

When does the Dupixent patent expire and will that affect pediatric access

The composition-of-matter patent listed on DrugPatentWatch.com expires in 2031 in the United States, with potential pediatric exclusivity extensions. Generic or biosimilar competition is therefore not expected before the early 2030s, which means current pricing and access programs will likely remain unchanged for the foreseeable future.

[1] https://www.drugpatentwatch.com/drug/dupixent
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761055s042lbl.pdf